UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics


UroGen Pharma Ltd. - Ordinary Shares (URGN)

Today's Latest Price: $25.36 USD

0.14 (-0.55%)

Updated Jul 2 4:00pm

Add URGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

URGN Stock Summary

  • With a one year PEG ratio of 0.31, UroGen Pharma Ltd is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 5.51% of US stocks.
  • For URGN, its debt to operating expenses ratio is greater than that reported by merely 0.34% of US equities we're observing.
  • URGN's price/sales ratio is 31,830.31; that's higher than the P/S ratio of 100% of US stocks.
  • Stocks that are quantitatively similar to URGN, based on their financial statements, market capitalization, and price volatility, are IMMU, GENE, CYAD, ADVM, and NK.
  • Visit URGN's SEC page to see the company's official filings. To visit the company's web site, go to www.urogen.com.
URGN Daily Price Range
URGN 52-Week Price Range

URGN Stock Price Chart Technical Analysis Charts


URGN Price/Volume Stats

Current price $25.36 52-week high $37.08
Prev. close $25.50 52-week low $13.12
Day low $24.89 Volume 147,760
Day high $25.87 Avg. volume 220,269
50-day MA $25.45 Dividend yield N/A
200-day MA $26.43 Market Cap 529.95M

UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio


UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.


URGN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

URGN Latest Social Stream


Loading social stream, please wait...

View Full URGN Social Stream

Latest URGN News From Around the Web

Below are the latest news stories about UroGen Pharma Ltd that investors may wish to consider to help them evaluate URGN as an investment opportunity.

Hedge Funds Are Selling UroGen Pharma Ltd. (URGN)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 16, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units ("RSUs") on June 3, 2020 to eight new employees in connection with their employment with UroGen. These new team members will support the Company’s commercial launch of JelmytoTM (mitomycin) for pyelocalyceal solution, its first approved product.

Yahoo | June 5, 2020

UroGen Pharma (URGN) Presents At Jefferies Healthcare Conference - Slideshow

The following slide deck was published by UroGen Pharma Ltd. in conjunction with this event....

SA Transcripts | June 3, 2020

UroGen Pharma to Present at Jefferies Virtual Healthcare Conference

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020, at 3:30 PM Eastern Time. A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen

Business Wire | June 1, 2020

UroGen Announces Positive Data from Pivotal OLYMPUS Trial Evaluating Jelmyto™ in Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd. (Nasdaq:URGN) today announced the presentation of positive data from the UGN-101 (Jelmyto™ (mitomycin) for pyelocalyceal solution) Phase 3 OLYMPUS trial in patients with low-grade upper tract urothelial cancer (LG-UTUC). The study was accepted for the 2020 American Urological Association (AUA) Annual Meeting, published as a supplement to the April 2020 issue of The Journal of Urology® and presented as part of the AUA Virtual Experience. The presentation can be accessed via the AUA website here. More information can also be accessed via UroGen’s virtual AUA experience here.

Yahoo | May 15, 2020

Read More 'URGN' Stories Here

URGN Price Returns

1-mo -3.10%
3-mo 38.05%
6-mo -20.45%
1-year -28.12%
3-year 35.36%
5-year N/A
YTD -24.00%
2019 -22.50%
2018 15.72%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8687 seconds.